A Phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors
Study of ST101 in Patients with Advanced Solid Tumors
Sponsor: Sapience Therapeutics Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT1892
U.S. Govt. ID: NCT04478279
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: With this research study, we want to find out which dose of ST101 is tolerable and effective for people with different types of cancer. We also want to see what the body does to ST101, where ST101 goes in the body, and how long it stays in the body. This study is the first time we have given ST101 to humans. Drugs that can only be used in research are sometimes called 'investigational drugs.' "Investigational" means the study drug/formulation/medical device being tested is not approved by the U.S. Food and Drug Administration (FDA).
Investigator
Fabio Iwamoto, MD
Do You Qualify?
Are you at least 18 years of age or older? Yes No
Are you able to perform every day tasks independently? Yes No
Did your cancer progress or not respond to previous treatment? Yes No
Do you have adequate organ function? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE